Grupo de Oncología Experimental

Mariano Barbacid Jefe de Grupo
T +34 912246933 (Ext 4000)
mbarbacid@cnio.es

Investigadores

Matthias Drosten
Raquel García
Carmen Guerra

Becarios Post-doctorales

Sara García
Guillem Paniagua

Becarios Pre-Doctorales

Oksana Brehey
Laura De la Puente
Sara Alexandra De Sousa
Fernando Fernández
Jing Li
Vasiliki Liaki
Lucía Morales
Marina Salmón

Técnicos de Laboratorio

Irene de Diego
Mª Carmen González
Patricia Teresa Guerra
Silvia Jiménez
Marta San Román
Raquel Villar

KRAS oncogenes have been identified in one fifth of all human cancers. Yet, no selective inhibitors have been approved so far. Moreover, attempts to block KRAS oncogenic activity with selective inhibitors of KRAS signalling pathways have failed so far due to unacceptable toxicities. In our laboratory, we have continued our quest to validate therapeutic targets for KRAS driven lung and pancreatic tumours using a new generation of genetically engineered mouse tumour models that allow us to evaluate their anti-tumour properties as well as their potential toxic effects in tumour-bearing mice. These studies have allowed the identification of RAF1 as the only target within the MAPK signalling pathway capable of inducing significant tumour regressions in advanced KRAS/ TRP53 mutant tumours without inducing major toxicities. We are now focusing our research interests on: (i) devising therapeutic strategies to selectively targeting RAF1 and (ii) identifying additional targets that may cooperate with RAF1 inhibition, with the ultimate goal of translating these results to the clinic.

Publicaciones

Drosten M, Barbacid M (2020). Targeting the MAPK Pathway in KRAS-Driven Tumors.. Cancer Cell 37, 543-550. Publicación CNIO.
Esteban-Burgos L, Wang H, Nieto P, Zheng J, Blanco-Aparicio C, Varela C, Gómez-López G, Fernández-García F, Sanclemente M, Guerra C, Drosten M, Galán J, Caleiras E, Martínez-Torrecuadrada J, Fajas L, Peng SB, Santamaría D, Musteanu M, Barbacid M (2020). Tumor regression and resistance mechanisms upon CDK4 and RAF1 inactivation in KRAS/P53 mutant lung adenocarcinomas. Proc Natl Acad Sci USA 117, 24415-24426. Publicación CNIO.
Nokin MJ, Darbo E, Travert C, Drogat B, Lacouture A, San José S, Cabrera N, Turcq B, Prouzet-Mauleon V, Falcone M, Villanueva A, Wang H, Herfs M, Mosteiro M, Jänne PA, Pujol JL, Maraver A, Barbacid M, Nadal E, Santamaría D, Ambrogio C (2020). Inhibition of DDR1 enhances in vivo chemosensitivity in KRAS-mutant lung adenocarcinoma. JCI Insight 5, 137869. Publicación CNIO.
Yao Z, Gao Y, Su W, Yaeger R, Tao J, Na N, Zhang Y, Zhang C, Rymar A, Tao A, Timaul NM, Mcgriskin R, Outmezguine NA, Zhao H, Chang Q, Qeriqi B, Barbacid M, de Stanchina E, Hyman DM, Bollag G, Rosen N (2019). RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat Med 25, 284-291. Publicación CNIO.
Quilichini E, Fabre M, Dirami T, Stedman A, De Vas M, Ozguc O, Pasek RC, Cereghini S, Morillon L, Guerra C, Couvelard A, Gannon M, Haumaitre C (2019). Pancreatic ductal deletion of Hnf1b disrupts exocrine homeostasis, leads to pancreatitis and facilitates tumorigenesis.. Cell Mol Gastroenterol Hepatol 8, 487-511. Publicación CNIO. Open Access
Barbacid M (2019). On the right TRK: from oncogene discovery to cancer therapeutics. Ann Oncol 30, viii3-viii4. Publicación CNIO.
García-Gutiérrez L, Bretones G, Molina E, Arechaga I, Symonds C, Acosta JC, Blanco R, Fernández A, Alonso L, Sicinski P, Barbacid M, Santamaría D, León (2019). Myc stimulates cell cycle progression through the activation of Cdk1 and phosphorylation of p27. Sci Rep 9, 18693. Publicación CNIO. Open Access
Blasco MT, Navas C, Martín-Serrano G, Graña-Castro O, Lechuga CG, Martín-Díaz L, Djurec M, Li Jing, Morales-Cacho L, Esteban-Burgos L, Perales-Patón J, Bousquet-Mur E, Castellano E, Jacob Harrys KC, Cabras L, Mustenau M, Drosten M, Ortega S, Mulero F, Sainz B, Dusetti N, Iovanna J, Sánchez-Bueno F, Hidalgo M, Khiabanian H, Hidalgo M, Rabadán R, Al-Shahrour F, Guerra C, Barbacid M (2019). Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. Cancer Cell 35, 573-587. Publicación CNIO.
Cussó L, Musteanu M, Mulero F, Barbacid M, Desco M (2019). Effects of a Ketogenic Diet on [18F]FDG-PET Imaging in a Mouse Model of Lung Cancer. Mol Imaging Biol 21, 279-285. Publicación CNIO.
Moll HP, Mohrherr J, Blaas L, Musteanu M, Stiedl P, Grabner B, Zboray K, König M, Stoiber D, Rülicke T, Strehl S, Eferl R, Casanova E (2019). A Mouse Model to Assess STAT3 and STAT5A/B Combined Inhibition in Health and Disease Conditions. Cancers 11, E1226. Publicación CNIO. Open Access
Y. Gao, M. Chang, D. McKay, N. Na, B. Zhou, R. Yaeger, N. Torres, K. Muniz, M. Drosten, M. Barbacid, G. Caponigro, D. Stuart, H. Möbitz, D. Solit, O. Abdel-Wahab, B. Taylor, Z. Yao, and N. Rosen (2018). Allele-specific mechanisms of activation of MEK1 mutants determine their properties. Cancer Discovery 8, 648-651. Publicación CNIO.
Moll HP, Pranz K, Musteanu M, Grabner B, Hruschka N, Mohrherr J, Aigner P, Stiedl P, Brcic L, Laszlo V, Schramek D, Moriggl R, Eferl R, Moldvay J, Dezso K, Lopez-Casas PP, Stoiber D, Hidalgo M, Penninger J, Sibilia M, Gyorffy B, Barbacid M, Dome B, Popper H, Casanova E (2018). Afatinib restrains K-RAS driven lung tumorigenesis. Sci Transl Med 10, 446. Publicación CNIO.
Orozco CA, Martinez-Bosch N, Guerrero PE, Vinaixa J, Iglesias M, Moreno M, Djurec M, Poirier F, Gabius HJ, Fernandez-Zapico M, Hwang RF, Guerra C, Rabinovich G and Navarro P (2018). Targeting galectin-1 inhibits pancreatic cancer progression by interrupting tumor-stroma cross-talk. Proc Natl Acad Sci USA 115, E3769-E3778. Publicación CNIO.
Mayor-Ruiz C, Olbrich T, Drosten M, Lecona E, Vega-Sendino M, Ortega S, Dominguez O, Barbacid M, Ruiz S, Fernandez-Capetillo O (2018). ERF deletion rescues RAS deficiency in mouse embryonic stem cells. Genes Dev 32, 568-576. Publicación CNIO. Open Access
Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M (2018). c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling. Cancer Cell 33, 217-228. Publicación CNIO.
Djurec M, Graña O, Lee A, Troulé K, Espinet E, Cabras L, Navas C, Blasco MT, Martín-Díaz L, Burdiel M, Li J, Liu Z, Vallespinós M, Sanchez-Bueno F, Sprick MR, Trumpp A, Sainz B Jr., Al-Shahrour F, Rabadan R, Guerra C, Barbacid M (2018). Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors. Proc Natl Acad Sci USA 115, E1147-E1156. Publicación CNIO.
Sonntag R, Giebeler N, Nevzorova YA, Bangen JM, Fahrenkamp D, Lambertz D, Haas U, Hu W, Gassler N, Cubero FJ, Müller-Newen G, Abdallah AT, Weiskirchen R, Ticconi F, Costa IG, Barbacid M, Trautwein C, Liedtke C (2018). Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma. Proc Natl Acad Sci USA 115, 9282-9287. Publicación CNIO.
Drosten M, Guerra C, Barbacid M (2018). Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets. Cold Spring Harb Perspect Med 8, a031542. Publicación CNIO.
Cussó L, Musteanu M, Mulero F, Barbacid M, Desco M (2018). Effects of a Ketogenic Diet on [18F]FDG-PET Imaging in a Mouse Model of Lung Cancer. Mol Imaging Biol 21, 279-285. Publicación CNIO.
Simón-Carrasco L, Jiménez G, Barbacid M, Drosten M (2018). The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer. Cell Cycle 17, 702-711. Publicación CNIO.
Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M and Santamaría D (2017). A Braf kinase-inactive mutant induces lung adenocarcinoma.. Nature 548, 239-243. Publicación CNIO.
Yao Z, Yaeger R, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Rodrik-Outmezguine VS, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS and Rosen N (2017). Tumors with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.. Nature 548, 234-238. Publicación CNIO.
Papale A, d'Isa R, Menna E, Cerovic M, Solari N, Hardingham N, Cambiaghi M, Cursi M, Barbacid M, Leocani L, Fasano S, Matteoli M, Brambilla R (2017). Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies.. Biol Psychiat 81, 179-192. Publicación CNIO.
Simón-Carrasco L, Graña O, Salmón M, Jacob HKC, Gutierrez A, Jiménez G, Drosten M, Barbacid M (2017). Inactivation of Capicua in adult mice causes T cell lymphoblastic lymphoma. Genes Dev 31, 1456-1468. Publicación CNIO.
Drosten M, Simón-Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HK, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M (2017). H-Ras and K-Ras oncoproteins induce different tumor spectra when driven by the same regulatory sequences.. Cancer Res 77, 707-718. Publicación CNIO.
Forés M, Simón-Carrasco L, Ajuria L, Samper N, González-Crespo S, Drosten M, Barbacid M, Jiménez G (2017). A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer. PLoS Genet 13, e1006622. Publicación CNIO.
Ambrogio C, Barbacid M, Santamaría D (2017). In vivo oncogenic conflicto triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.. Oncogene 36, 2309-2318. Publicación CNIO.
Chirivella L, Kirstein M, Ferrón SR, Domingo-Muelas A, Durupt FC, Acosta-Umanzor C, Cano-Jaimez M, Pérez-Sánchez F, Barbacid M, Ortega S, Burks D, Fariñas I (2017). Cdk4 regulates adult neural stem cell proliferation and differentiation in response to insulin-IRS2 signals.. Stem Cells 35, 2403-2416. Publicación CNIO.
Schreiber J, Grimbergen LA, Overwater I, Vaart TV, Stedehouder J, Schuhmacher AJ, Guerra C, Kushner SA, Jaarsma D, Elgersma Y (2017). Mechanisms underlying cognitive deficits in a mouse model for Costello Syndrome are distinct from other RASopathy mouse models. Sci Rep 7, 1256. Publicación CNIO.
Drosten M, Guerra C and Barbacid M (2017). Genetically engineered mouse models of K-Ras driven lung and pancreatic tumors: Validation of therapeutic targets. In Additional Perspectives on Ras and Cancer in the 21st Century (ed. L. VanAelst, J. Downward and F. McCormick).. Cold Spring Harbor Laboratory Press (in press). Publicación CNIO.
Hernández-Porras I, Guerra C (2017). Modeling Rasopathies with genetically modified mouse models.. Methods Mol Biol 1487, 379-408. Publicación CNIO.
Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P. (2017). The European Cancer Patient’s Bill of Rights, update and implementation 2016.. ESMO OPEN 1, e000127. Publicación CNIO.
Lechuga CG, Simón-Carrasco L, Jacob HKC, Drosten M (2017). Genetic validation of cell proliferation via Ras-independent activation of the Raf/Mek/Erk pathway.. Methods Mol Biol 1487, 269-276. Publicación CNIO.
Schuhmacher AJ, Hernández-Porras I, García-Medina R, Guerra C (2017). Lessons learnt from genetic studies in mice into Noonan syndrome.. Expert Review of Endocrinology and Metabolism 12, 367-378. Publicación CNIO.
Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M (2016). Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.. Nat Med 22, 270-277. Publicación CNIO.
Martinelli P, Madriles F, Cañamero M, Pau EC, Pozo ND, Guerra C, Real FX. (2016). The acinar regulator Gata6 suppresses KrasG12V-driven pancreatic tumorigenesis in mice.. Gut 65, 476-486. Publicación CNIO.
Hernández-Porras I, Schuhmacher AJ, Garcia-Medina R, Jiménez B, Cañamero M, de Martino A, Guerra C (2016). K-Ras(V14I) -induced Noonan syndrome predisposes to tumour development in mice.. J Pathol 239, 206-217. Publicación CNIO.
Ambrogio C, Barbacid M, Santamaría D (2016). In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.. Oncogene (in press). Publicación CNIO.
Augereau C, Collet L, Vargiu P, Guerra C, Ortega S, Lemaigre FP, Jacquemin P (2016). Chronic pancreatitis and lipomatosis are associated with defective function of ciliary genes in pancreatic ductal cells.. Hum Mol Genet 25, 5017-5026. Publicación CNIO.
Drosten M, Barbacid M (2016). Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.. J Mol Med-Jmm 94, 121-135. Publicación CNIO.
Lopez S, Voisset E, Tisserand JC, Mosca C, Prebet T, Santamaria D, Dubreuil P, De Sepulveda P (2016). An essential pathway links FLT3-ITD, HCK and CDK6 in acute myeloid leukemia. Oncotarget 7, 51163-51173. Publicación CNIO. Open Access
Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D (2016). KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.. ESMO OPEN 1, e000076. Publicación CNIO.